Go back

NantWorks to inject US$200m into South African R&D partnership

Image: Sanofi Pasteur [CC BY-NC-ND 2.0], via Flickr

Cutting-edge vaccine platform among technology company’s ambitions

South Africa announced a multi-billion rand health research partnership on 23 September. The deal, with United States-based company NantWorks, will focus on Covid-19 vaccines, cancer, and infectious diseases.

“We are committed to invest and support R3 billion. That is the beginning of what would be needed,” said Patrick Soon-Shiong, the South Africa-born head of NantWorks, during the launch webinar. R3bn is about US$200 million.

This article is only available to Research Professional News subscribers. If you are a subscriber you can read the article in full on researchprofessional.com

Pivot-RP users can log in and view the article via this link.